[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611387":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":10,"responsibleParty":36,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":61,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":10},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Case Group",null,"R-CAD patients",[13],"Diagnostic Test: Protocol-defined Examinations and Evaluations",{"label":15,"type":10,"description":16,"interventionNames":17},"Control Group","NR-CAD patients",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Protocol-defined Examinations and Evaluations","Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, 6-minute walk test, vascular ultrasound, coronary angiography, optical coherence tomography (OCT), fibroblast activation protein inhibitor positron emission tomography\u002Fcomputed tomography (FAPI-PET\u002FCT), photon-counting detector coronary computed tomography angiography (PCD-CCTA), tests for exploratory biomarkers.",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Zhenyu Liu, M.D.","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+861069155068","Pumch_lzy@163.com",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Lihong Xu, B.N.","xulihong1990@163.com",{"type":27,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"LiuZhenyu","Professor","100611387","disease-characteristics-of-r-cad-100611387",false,"NCT07239921","Disease Characteristics of R-CAD","Disease Characteristics of Rapidly Progressive Coronary Artery Disease (R-CAD): A Case-control Study","Inclusion Criteria:\n\nCase Group (R-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or CABG).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization.\n5. Rapidly progressive myocardial ischemia leading to hospitalization and\u002For coronary revascularization:\n\n   1. Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] classification III-IV) and non-invasive evidence of myocardial ischemia; and\n   2. Occurred within 6 months of the latest ischemia-driven hospitalization and\u002For coronary revascularization.\n6. Rapidly progressive coronary lesions leading to myocardial ischemia:\n\n   1. Angiographic evidence of new-onset or worsened coronary de novo or restenotic lesions relevant to myocardial ischemia, and\n   2. Occurred within 6 months of the latest ischemia-driven coronary angiography and\u002For revascularization.\n\nControl Group (NR-CAD patients):\n\n1. 35 to 75 years old\\*, male or female. (\\* Based on the age distribution characteristics of patients who have been diagnosed as R-CAD.)\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, at 12±6 months after the latest PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the index hospitalization.\n6. No evidence of rapidly progressive myocardial ischemia and coronary lesions, i.e., not fulfilling items 5) and 6) of the inclusion criteria for R-CAD.\n\nExclusion Criteria:\n\n1. Receiving immunosuppressive therapy within 6 months.\n2. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n3. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n8. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n9. Previous enrollment in this study.\n10. Participation in another study within 30 days.\n11. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n12. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.","ALL","18 Years",{"count":49,"type":50},52,"ESTIMATED","OBSERVATIONAL","The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease \\[NR-CAD\\]).",[54,55,56,57,58,59,60],"Coronary Artery Disease","Coronary Artery Disease Progression","Coronary Stenosis","Coronary Restenosis","Coronary Stent Occlusion","Myocardial Revascularization","Percutaneous Coronary Intervention",[54,56,57,59,60,62,63],"Disease Progression","Disease Attributes","NOT_YET_RECRUITING","2025-11-21",{"date":67,"type":68},"2025-11-28","ACTUAL",{"date":70,"type":50},"2025-11",{"date":72,"type":50},"2026-10",{"name":5,"class":6}]